Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "non-alcoholic fatty liver" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-8 z 8
    Tytuł:
    The effect of probiotic supplementation as alternative therapy for NAFLD: a literature review
    Autorzy:
    Adnan, Muhammad Luthfi
    Powiązania:
    https://bibliotekanauki.pl/articles/1891281.pdf
    Data publikacji:
    2021-12-02
    Wydawca:
    Gdański Uniwersytet Medyczny
    Tematy:
    Non-alcoholic fatty liver disease
    NAFLD
    probiotic
    therapy
    Opis:
    Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases, influenced by various risk factors associated with metabolic disorders. Currently there is no specific effective treatment for NAFLD. Probiotics have been extensively researched for their health benefit Probiotic Supplementation for NAFLD. Methods: A simple literature review was performed based on searches via PubMed, ScienceDirect and Google Scholar, using the keywords "probiotic," "microbiota," "non-alcoholic fatty liver disease," "metabolic disorder," and "therapy." Results: Research on the use of probiotics for NAFLD demonstrated improvement in liver function and histology. However, the literature is inconsistent regarding the probiotics’ influence on the NAFLD risk factors. Probiotics can be an alternative therapy for NAFLD through the ability to modulate the microbiota of the gastrointestinal tract. Conclusion: Probiotics can be an alternative therapy in NAFLD patients, however more extensive studies are needed to ensure the safety of this approach.
    Źródło:
    European Journal of Translational and Clinical Medicine; 2021, 4, 2; 75-85
    2657-3148
    2657-3156
    Pojawia się w:
    European Journal of Translational and Clinical Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Cardiometabolic risk prediction in patients with non-alcoholic fatty liver disease combined with subclinical hypothyroidism
    Przewidywanie ryzyka kardiometabolicznego u pacjentów z niealkoholową stłuszczeniową chorobą wątroby w połączeniu z subkliniczną niedoczynnością tarczycy
    Autorzy:
    Kolesnikova, Olena
    Vуsotska, Olena
    Potapenko, Anna
    Radchenko, Anastasia
    Trunova, Anna I.
    Virstyuk, Nataliya
    Vasylevska-Skupa, Liudmyla
    Kalizhanova, Aliya
    Mukanova, Nazerka
    Powiązania:
    https://bibliotekanauki.pl/articles/27315426.pdf
    Data publikacji:
    2023
    Wydawca:
    Politechnika Lubelska. Wydawnictwo Politechniki Lubelskiej
    Tematy:
    cardiometabolic risk
    non-alcoholic fatty liver disease
    subclinical hypothyroidism
    prediction
    binary regression logistic analysis
    validation of prognostic models
    ryzyko kardiometaboliczne
    niealkoholowe stłuszczenie wątroby
    subkliniczna niedoczynność tarczycy
    rokowanie
    binarna analiza regresji logistycznej
    walidacja modeli prognostycznych
    Opis:
    One of the most common diseases of our time is non-alcoholic fatty liver disease (NAFLD). Recently published research results indicate that patients with NAFLD along with traditional risk factors for cardiovascular diseases (CVD) have "new"risk factors such as endothelial dysfunction (ED), carotid intima-media thickness (CIMT), an increase in the CRP level, as well as risk factors combined into the Framingham scale. It is also knownthat combination of NAFLD with subclinical hypothyroidism (SH) forms an abnormal metabolic phenotype, which is associated with cardiometabolicrisk factors. The study of cardiometabolic predictors and vascular markers in patients with NAFLD in combination with SH willprovide an opportunityto improve the strategy of cardiovascular events prevention in such comorbid patients.
    Niealkoholowe stłuszczenie wątroby (NAFLD) jest jedną z najczęstszych chorób naszych czasów. Ostatnio opublikowane wyniki badań sugerują, że pacjenci z NAFLD, wraz z tradycyjnymi czynnikami ryzyka chorób sercowo-naczyniowych (CVD), mają "nowe" czynniki ryzyka, takie jak dysfunkcja śródbłonka (ED), grubość błony wewnętrznej i środkowej tętnicy szyjnej (CIMT), podwyższony poziom CRP i czynniki ryzyka połączone w skali Framingham. Wiadomo również, że połączenie NAFLD z subkliniczną niedoczynnością tarczycy (SH) tworzy nieprawidłowy fenotyp metaboliczny związany z czynnikami ryzyka kardiometabolicznego. Badanie predyktorów kardiometabolicznych i markerów naczyniowych u pacjentów z NAFLDw połączeniu z SH pozwoli na ulepszenie strategii zapobiegania zdarzeniom sercowo-naczyniowym u takich współistniejących pacjentów.
    Źródło:
    Informatyka, Automatyka, Pomiary w Gospodarce i Ochronie Środowiska; 2023, 13, 2; 64--68
    2083-0157
    2391-6761
    Pojawia się w:
    Informatyka, Automatyka, Pomiary w Gospodarce i Ochronie Środowiska
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Hepatokines and non-alcoholic fatty liver disease
    Autorzy:
    Lebensztejn, Dariusz
    Flisiak-Jackiewicz, Marta
    Białokoz-Kalinowska, Irena
    Bobrus-Chociej, Anna
    Kowalska, Irina
    Powiązania:
    https://bibliotekanauki.pl/articles/1038763.pdf
    Data publikacji:
    2016
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    non-alcoholic fatty liver disease
    fetuin-A
    fibroblast growth factor-21
    selenoprotein P
    sex hormone-binding globulin
    angiopoietin-related growth factor
    leukocyte derived chemotaxin 2
    Opis:
    Nowadays non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver pathology both in adults and children. NAFLD manifestation ranges from a simple liver steatosis to steatohepatitis (nonalcoholic steatohepatitis - NASH), which may progress to advanced fibrosis, cirrhosis and end-stage liver disease. Due to the coexistence of visceral obesity, insulin resistance and dyslipidemia, NAFLD is considered to be the hepatic manifestation of metabolic syndrome. In recent years, in the pathogenesis of metabolic syndrome, type 2 diabetes mellitus, cardiovascular disease and also NAFLD, more and more attention has been paid to the so-called organokines, proteins with both paracrine or/and endocrine activities. These include most known adipokines (mainly produced by adipose tissue), myokines (mainly produced by skeletal muscles) and hepatokines exclusively or predominantly produced by the liver. It was shown that the liver may affect the lipids and glucose metabolism by hepatokines released into the blood and NAFLD seems to be associated with altered hepatokines production. Fetuin-A, fibroblast growth factor-21 (FGF-21), selenoprotein P, sex hormone-binding globulin (SHBG), angiopoietin-related growth factor (also known as angiopoietin-related protein 6) and leukocyte derived chemotaxin 2 (LECT2) are considered as the most important hepatokines. In this review, we provide an overview of the main hepatokines and we summarize the association of liver-derived proteins with the development and progression of NAFLD.
    Źródło:
    Acta Biochimica Polonica; 2016, 63, 3; 459-467
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Influence of oleic acid in different solvent media on BRL 3A cell growth and viability
    Autorzy:
    Liu, Runqi
    Yang, Wei
    Xia, Cheng
    Chen, Yuanyuan
    Gao, Sansi
    Dong, Zhihao
    Huang, Baoyin
    Li, Ruirui
    He, Ping
    Xu, Chuang
    Powiązania:
    https://bibliotekanauki.pl/articles/1038377.pdf
    Data publikacji:
    2018
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    oleic acid
    non-alcoholic fatty liver disease
    liver lipid deposition
    Opis:
    Oleic acid (OA) is widely used in pathology studies of hepatocellular lipid deposition. Identifying the effects of different solvents on OA-induced liver lipid deposition would be beneficial for studies on hepatocytes. We treated BRL 3A cells with OA dissolved in different solvents. After 12 h incubation, cell viability was assessed using MTT assays. Reactive oxygen species (ROS), triglyceride (TG) and total cholesterol (TC) counts, and the expression level of glucose regulated protein (GRP78), sterol regulatory element binding protein (SREBP-1C) and fatty acid synthase (FAS) were analyzed. Water, PBS and DMSO were disadvantageous to the dissolution of OA and did not cause an OA-induced response in hepatocytes. In the alcohol+OA-treated cells, the severe ER stress, oxidative stress and cellular fat deposition were significantly increased. BSA promoted cell growth and the cells treated with 1.2% BSA+OA showed a lower grade TG and endoplasmic reticulum stress compared with KOH+OA and alcohol+OA treatments. KOH had no significant influence on BRL 3A cells viability. When treated with OA dissolved in KOH, BRL 3A cells showed a typical hepatocyte damage. KOH was considered the suitable choice for an OA solvent for BRL 3A cells in hepatic lipidosis research.
    Źródło:
    Acta Biochimica Polonica; 2018, 65, 3; 443-447
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Impact of bariatric surgery on non-alcoholic fatty liver disease
    Autorzy:
    Major, Piotr
    Pędziwiatr, Michał
    Rubinkiewicz, Mateusz
    Stanek, Maciej
    Głuszewska, Anna
    Pisarska, Magdalena
    Małczak, Piotr
    Budzyński, Andrzej
    Budzyński, Piotr
    Powiązania:
    https://bibliotekanauki.pl/articles/1393188.pdf
    Data publikacji:
    2017
    Wydawca:
    Index Copernicus International
    Tematy:
    non-alcoholic fatty liver disease
    bariatric surgery
    morbid obesity
    Opis:
    Introduction; p to 300 million people have the body mass index (BMI) greater than 30 kg/m2. Obesity is the cause of many serious diseases, such as type 2 diabetes, hypertension, and non-alcoholic fatty liver disease (NAFLD). Bariatric surgery is the only effective method of achieving weight loss in patients with morbid obesity. Objectives: The aim of the study was to assess the impact of bariatric surgery on non-alcoholic fatty liver disease in patients operated on due to morbid obesity. Material and Methods: We included 20 patients who were qualified for bariatric procedures based on BMI > 40 kg/ m2 or BMI > 35kg/m2 with the presence of comorbidities. The average body weight in the group was 143.85kg, with an average BMI of 49.16kg/m2. Before the procedure, we evaluated the severity of non-alcoholic fatty liver disease in each patient using the Sheriff-Saadeh ultrasound scale. We also evaluated the levels of liver enzymes. Follow-up evaluation was performed twelve months after surgery. Results: Twelve months after surgery, the average weight was 102.34 kg. The mean %WL was 33.01%, %EWL was 58.8%, and %EBMIL was 61.37%. All patients showed remission of fatty liver disease. Liver damage, evaluated with ultrasound imaging, decreased from an average of 1.85 on the Sheriff-Saadeh scale, before surgery, to 0.15 twelve months after surgery (p < 0.001). As regards liver enzymes, the level of alanine aminotransferase decreased from 64.5 (U/l) to 27.95 (U/l) (p < 0.001), and the level of aspartate aminotransferase decreased from 54.4 (U/l) to 27.2 (U/l). Conclusions: Bariatric procedures not only lead to a significant and lasting weight loss, but they also contribute to the reduction of fatty liver disease and improve liver function.
    Źródło:
    Polish Journal of Surgery; 2017, 89, 2; 1-4
    0032-373X
    2299-2847
    Pojawia się w:
    Polish Journal of Surgery
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Prevalence of non-alcoholic fatty liver disease and hypercholesterolemia in patients with gallstone disease undergoing laparoscopic cholecystectomy
    Autorzy:
    Singh, Kaptan
    Dahiya, Divya
    Kaman, Lileswar
    Das, Ashim
    Powiązania:
    https://bibliotekanauki.pl/articles/1391850.pdf
    Data publikacji:
    2020
    Wydawca:
    Index Copernicus International
    Tematy:
    dyslipidemia
    gallstone disease
    liver biopsy
    non-alcoholic fatty liver disease (NAFLD)
    Opis:
    Background: Gallstone disease (GSD) and nonalcoholic fatty liver disease (NAFLD) are connected with a high prevalence in the general population and they share common risk factors for their occurrence. Limited literature with inconsistent results is available, suggesting a potential association between these lifestyle-induced diseases. Liver biopsy is the gold standard for diagnosing NAFLD. The aim of this study was (1) to identify the prevalence of asymptomatic NAFLD or NASH in liver biopsy; (2) to identify the association of hypercholesterolemia with NAFLD in patients undergoing laparoscopic cholecystectomy (LC). Methods: This is a prospective observational study conducted on patients who underwent LC for symptomatic gallstones in the Department of General Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India, from 1st July 2013 to 31st December 2014. All included patients had ultrasonography (USG) and the following parameters tested: serum triglycerides (TG), cholesterol, low density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). A wedge liver biopsy was obtained from free edge of the right liver lobe during LC and all biopsy specimens were analyzed by a single pathologist. Results: Among 101 patients included in the study, dyslipidemia was present in 49.50%. There was no association between NAFLD and serum cholesterol, TG or LDL-C (P, 0.428, 0.848, 0.371 respectively). NAFLD was confirmed in liver biopsy in 21.8% of patients but none had fibrosis or cirrhosis on biopsy. No complications were observed following liver biopsy. Conclusions: Liver biopsy during LC gives an opportunity to diagnose the disease at an early and reversible stage. It is feasible, safe and cost effective.
    Źródło:
    Polish Journal of Surgery; 2020, 92, 1; 18-22
    0032-373X
    2299-2847
    Pojawia się w:
    Polish Journal of Surgery
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    A prospective, interventional clinical study to evaluate the safety and efficacy of Liv.52 DS in the management of non-alcoholic fatty liver disease
    Autorzy:
    Siregar, Gontar
    Paramesh, Rangesh
    Kumawat, Rajesh
    D, Palaniyamma
    HA, Srikrishna
    Powiązania:
    https://bibliotekanauki.pl/articles/2038171.pdf
    Data publikacji:
    2021-06-30
    Wydawca:
    Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
    Tematy:
    ALT/AST
    fatty liver
    fibrosis
    non-alcoholic fatty liver disease
    Opis:
    Introduction. Non-alcoholic fatty liver disease (NAFLD) is excessive fat build-up in the liver due to causes other than alcohol use. Aim. To evaluate the clinical efficacy and safety of Liv.52 DS tablets in the management of NAFLD. Material and methods. Prospective, interventional clinical study conducted on 60 patients of both sex, aged between 18-65 years, confirmed with NAFLD from clinical examination, laboratory test, ultrasound findings and those willing to give informed consent. All patients received Liv.52 DS at a dose of 2 tablets twice daily for 2 months. All patients were evaluated at baseline, end of 1st month, and end of 2nd month for liver function tests, hepatomegaly by ultrasound, NAFLD Fibrosis Score, lipid profile, hematology and biochemical investigations. Results. Study data was analyzed with GraphPad Prism Software Version 6.07. Data of those patients who completed the study was considered for analysis. Significant improvement in hepatomegaly, liver enzymes was observed. NAFLD fibrosis score revealed no progression of liver fibrosis due to NAFLD during the study period. No abnormal lab values were recorded and there were no adverse events reported during the study. Conclusion. Study concludes that Liv.52 DS is safe and beneficial in individuals suffering from NAFLD.
    Źródło:
    European Journal of Clinical and Experimental Medicine; 2021, 2; 129-136
    2544-2406
    2544-1361
    Pojawia się w:
    European Journal of Clinical and Experimental Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Impaired base excision repair is related to the pathogenesis of non-alcoholic fatty liver disease
    Autorzy:
    Ziółkowska, Sylwia
    Czarny, Piotr
    Szemraj, Janusz
    Powiązania:
    https://bibliotekanauki.pl/articles/1024273.pdf
    Data publikacji:
    2020-12-30
    Wydawca:
    Uniwersytet Łódzki. Wydawnictwo Uniwersytetu Łódzkiego
    Tematy:
    DNA repair
    non-alcoholic fatty liver
    base excision repair
    Opis:
    Non-alcoholic fatty disease (NAFLD) is a liver disorder that affects up to 30% of the population, mainly in Western countries. It is estimated that up to 75% of NAFLD patients will develop a more aggressive form of the disease, non-alcoholic steatohepatitis (NASH). NAFLD can lead to fibrosis and liver failure; however, it is difficult to diagnose NAFLD due to its non-specific symptoms. Unfortunately, there is no treatment available for this disease. The risk factors of NAFLD are obesity and insulin resistance (IR). The molecular factors that seem to play an important role in the pathogenesis of NAFLD are oxidative stress as well as impaired DNA damage repair processes; a great body of evidence confirms an association with the base excision repair (BER) pathway. The activity of BER is decreased in patients with NAFLD and in animal models of this disease. In order to better understand the underlying basis of the disease, knowledge should be broadened in the area of DNA repair in NAFLD.
    Źródło:
    Acta Universitatis Lodziensis. Folia Biologica et Oecologica; 2020, 16; 5-11
    1730-2366
    2083-8484
    Pojawia się w:
    Acta Universitatis Lodziensis. Folia Biologica et Oecologica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-8 z 8

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies